索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]权力,张艳达,赵健,等.化疗药物致心脏毒性的可能机制及干预措施[J].国际心血管病杂志,2021,02:98-101.
点击复制

化疗药物致心脏毒性的可能机制及干预措施(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2021年02期
页码:
98-101
栏目:
综述
出版日期:
2021-03-20

文章信息/Info

Title:
-
作者:
权力; 张艳达; 赵健; 贺治青; 丁茹; 梁春
200003 上海,海军军医大学附属长征医院心内科
Author(s):
-
关键词:
化疗药物;  心脏毒性;  阿霉素
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2021.02.009
文献标识码:
-
摘要:
化疗是肿瘤治疗的重要手段,但化疗药物在提高恶性肿瘤患者生存率的同时也具有心脏毒性。对于化疗药物所致心脏毒性的机制、监测、治疗等方面研究已有很大进展。目前已探明的主要机制有诱导心肌细胞凋亡、产生活性氧、改变线粒体功能、诱导基质重构等。干预化疗所致心血管毒性的药物,也基本通过改变以上机制起作用。
Abstract:
-

参考文献/References

[1] Chang HM, Moudgil R, Scarabelli T, et al. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1[J]. J Am Coll Cardiol, 2017, 70(20):2536-2551.
[2] Chang HM, Okwuosa TM, Scarabelli T, et al. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 2[J]. J Am Coll Cardiol, 2017, 70(20):2552-2565.
[3] Cardinale D, Colombo A, Torrisi R, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponinⅠevaluation[J]. J Clin Oncol, 2010, 28(25):3910-3916.
[4] Magdy T, Burmeister BT, Burridge PW. Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?[J]. Pharmacol Ther, 2016, 168:113-125.
[5] Calvillo-Argüelles O, Abdel-Qadir H, Suntheralingam S, et al. Trastuzumab-related cardiotoxicity and cardiac care in patients with HER2 positive metastatic breast cancer[J]. Am J Cardiol, 2020, 125(8):1270-1275.
[6] Dolladille C, Ederhy S, Allouche S, et al. Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors[J]. J Immunother Cancer, 2020, 8(1):e000261.
[7] Visvikis A, Kyvelou S M, Pietri P, et al. Cardiotoxic profile and arterial stiffness of adjuvant chemotherapy for colorectal cancer[J]. Cancer Manag Res, 2020, 12:1175-1185.
[8] Favreau-Lessard AJ, Blaszyk H, Jones MA, et al. Systemic and cardiac susceptibility of immune compromised mice to doxorubicin[J]. Cardiooncology, 2019, 5:2.
[9] Wang Z, Zhang H, Shi M, et al. TAK1 inhibitor NG25 enhances doxorubicin-mediated apoptosis in breast cancer cells[J]. Sci Rep, 2016, 6:32737.
[10] Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity[J]. Nat Med, 2012, 18(11):1639-1642.
[11] Tay WT, Fang YH, Beh ST, et al. Programmed cell death-1: programmed cell death-ligand 1 interaction protects human cardiomyocytes against T-cell mediated inflammation and apoptosis response in vitro[J]. Int J Mol Sci, 2020, 21(7):2399.
[12] Xia P, Chen J, Liu Y, et al. Doxorubicin induces cardiomyocyte apoptosis and atrophy through cyclin-dependent kinase 2-mediated activation of forkhead box O1[J]. J Biol Chem, 2020, 295(13):4265-4276.
[13] Abdullah CS, Alam S, Aishwarya R, et al. Doxorubicin-induced cardiomyopathy associated with inhibition of autophagic degradation process and defects in mitochondrial respiration[J]. Sci Rep, 2019, 9(1):2002.
[14] Li DL, Wang ZV, Ding G, et al. Doxorubicin blocks cardiomyocyte autophagic flux by inhibiting lysosome acidification[J]. Circulation, 2016, 133(17):1668-1687.
[15] Li M, Sala V, De Santis M C, et al. Phosphoinositide 3-kinase gamma inhibition protects from anthracycline cardiotoxicity and reduces tumor growth[J]. Circulation, 2018, 138(7):696-711.
[16] Dhingra R, Guberman M, Rabinovich-Nikitin I, et al. Impaired NF-kappaB signalling underlies cyclophilin D-mediated mitochondrial permeability transition pore opening in doxorubicin cardiomyopathy[J]. Cardiovasc Res, 2020, 116(6):1161-1174.
[17] Chan BYH, Roczkowsky A, Cho W J, et al. MMP inhibitors attenuate doxorubicin cardiotoxicity by preventing intracellular and extracellular matrix remodeling[J]. Cardiovasc Res, 2020:cvaa017.
[18] Hu YH, Liu J, Lu J, et al. sFRP1 protects H9c2 cardiac myoblasts from doxorubicin-induced apoptosis by inhibiting the Wnt/PCP-JNK pathway[J]. Acta Pharmacol Sin, 2020.41(9):1150-1157.
[19] Tan L, Su X, Li X et al. Correlation of HER2 codon 655 polymorphism with cardiotoxicity risk in Chinese HER2-positive breast cancer patients undergoing epirubicin/cyclophosphamide followed by docetaxel plus trastuzumab adjuvant chemotherapy[J]. Int J Clin Exp Pathol, 2020, 13(2):286-294.
[20] Garcia-Pavia P, Kim Y, Restrepo-Cordoba M A, et al. Genetic variants associated with cancer therapy-induced cardiomyopathy[J]. Circulation, 2019, 140(1):31-41.
[21] Ky B, Putt M, Sawaya H, et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab[J]. J Am Coll Cardiol, 2014, 63(8):809-816.
[22] Hawkins PG, Sun Y, Dess RT, et al. Circulating microRNAs as biomarkers of radiation-induced cardiac toxicity in non-small-cell lung cancer[J]. J Cancer Res Clin Oncol, 2019, 145(6):1635-1643.
[23] Finkelman BS, Putt M, Wang T, et al. Arginine-nitric oxide metabolites and cardiac dysfunction in patients with breast cancer[J]. J Am Coll Cardiol, 2017, 70(2):152-162.
[24] Awadalla M, Mahmood SS, Groarke JD, et al. Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis[J]. J Am Coll Cardiol, 2020, 75(5):467-478.
[25] Pereira GC, Pereira SP, Pereira FB, et al. Early cardiac mitochondrial molecular and functional responses to acute anthracycline treatment in wistar rats[J]. Toxicol Sci, 2019, 169(1):137-150.
[26] Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology(ESC)[J]. Eur Heart J, 2016, 37(36):2768-2801.
[27] van Dalen EC, Caron HN, Dickinson HO, et al. Cardioprotective interventions for cancer patients receiving anthracyclines[J]. Cochrane Database Syst Rev, 2011(6):CD003917.
[28] Lam PY, Kutchukian P, Anand R, et al. Cyp1 inhibition prevents doxorubicin-induced cardiomyopathy in a zebrafish heart-failure model[J]. Chembiochem, 2020, 21(13):1905-1910.
[29] Shi C, Wu H, Xu K, et al. Liquiritigenin-loaded submicron emulsion protects against doxorubicin-induced cardiotoxicity via antioxidant, anti-inflammatory, and anti-apoptotic activity[J]. Int J Nanomedicine, 2020, 15:1101-1115.
[30] Jain A, Rani V. Mode of treatment governs curcumin response on doxorubicin-induced toxicity in cardiomyoblasts[J]. Mol Cell Biochem, 2018, 442(1-2):81-96.

备注/Memo

备注/Memo:
基金项目:国家自然科学基金(81473445, 91539118, 81611130092), 上海市中西医临床协作试点项目(ZY2018-2020-FWTX-1102), 上海市科学委员会中医引导类项目(17401934200)
通信作者:梁春,E-mail: chunliang@smmu.edu.cn
更新日期/Last Update: 2021-03-20